Hesperetin-containing composition and its synergistic application in lowering blood sugar

Hesperetin compositions with galangin or formononetin effectively inhibit α-glucosidase, addressing drug resistance and side effects in diabetes treatment by enhancing hypoglycemic activity and reducing drug dosage.

JP7588274B2Active Publication Date: 2024-11-21ZHENGZHOU FRUIT RES INST CHINESE ACADEMY OF AGRI SCI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024504013
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-08-20
Filing Date
2022-08-10
Publication Date
2024-11-21
Estimated Expiration
2042-08-10

AI Technical Summary

Technical Problem

Current treatments for diabetes, particularly type II diabetes, using single α-glucosidase inhibitors are prone to drug resistance and side effects, and there is a lack of research on synergistic effects between active molecules.

Method used

A hesperetin-containing composition combined with galangin or formononetin, in specific mass ratios, is used to inhibit α-glucosidase activity, thereby controlling postprandial blood sugar levels and reducing drug resistance.

Benefits of technology

The hesperetin compositions demonstrate a significant synergistic effect in inhibiting α-glucosidase, enhancing hypoglycemic activity, and reducing the dosage required, while minimizing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588274000018
    Figure 0007588274000018
  • Figure 0007588274000019
    Figure 0007588274000019
  • Figure 0007588274000020
    Figure 0007588274000020
Patent Text Reader

Abstract

The present invention discloses a hesperetin-containing composition and its synergistic application in lowering blood glucose, which belongs to the technical field of natural active compounds. The composition of the present invention comprises hesperetin and compound X, said compound X being galangin or formononetin, wherein the mass ratio of hesperetin to galangin is 30:100, and the mass ratio of hesperetin to formononetin is 30:20. The composition of the present invention has a significant synergistic effect for inhibiting α-glucosidase, which is superior to the use of said flavonoid compound alone, and can reduce the dosage of the drug used and suppress the occurrence of drug resistance.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the technical field of natural active compounds, specifically to a hesperetin-containing composition and its synergistic application in lowering blood glucose. [Background technology]

[0002] Diabetes mellitus is a worldwide chronic disease diagnosed by persistent hyperglycemia, including type I diabetes, type II diabetes, gestational diabetes, and other special diabetes. Type II diabetes, also known as non-insulin-dependent diabetes, accounts for more than 95% of diabetes cases. α-Glucosidase is a carbohydrate hydrolase that catalyzes the release of α-glucose from the non-reducing end of the substrate. α-Glucosidase is present in the majority of microorganisms, plants, and animals and is an essential enzyme in the metabolic pathway from starch to glucose. If α-glucosidase activity is too high in the body, it can lead to high blood glucose in the body and cause diabetes. Currently, insulin, sulfonylurea drugs, biguanides, thiazolidinediones, α-glucosidase inhibitors, etc. are commonly used clinically to treat diabetes, but long-term use of these drugs can cause side effects such as hypoglycemia, abdominal pain, vomiting, and diarrhea. α-glucosidase inhibitors delay carbohydrate absorption by competitively inhibiting the activity of α-glucosidase, thereby reducing postprandial and fasting blood glucose levels. Naturally derived α-glucosidase inhibitors have become a hot research topic in the fields of medicine, pharmacology and functional foods because they are environmentally friendly, safe and have few harmful side effects. Many research scholars at home and abroad have devoted themselves to the extraction, purification, isolation and identification of α-glucosidase inhibitors from plant resources, aiming to develop novel, efficient and non-toxic drugs for the treatment of diabetes and its complications. For example, polyphenolic compounds such as flavonoids, phenolic acids and tannic acids are common plant-derived ingredients that inhibit α-glucosidase activity.

[0003] Drug combination is the simultaneous or sequential application of two or more drugs for therapeutic purposes, which mainly aims to enhance drug therapy or reduce the harmful side effects of drugs, but sometimes leads to the opposite result. Therefore, rational combination therapy of drugs should be based on the basic principle of improving the therapeutic effect and (or) reducing the side effects. When both drugs are used together to achieve synergistic effects, the therapeutic effect of both drugs may be significantly improved than that of single drug administration. Currently, most of the research on α-glucosidase inhibitors focuses on single compounds, which are accompanied by certain side effects and resistance with continued use, but little is reported about the synergistic effect between active molecules. Therefore, research on the combination of flavonoid compounds that inhibit α-glucosidase and enhance the hypoglycemic effect is important for the promotion of human health. Summary of the Invention

[0004] The present invention aims to provide a hesperetin-containing composition and its synergistic application in lowering blood glucose, in order to solve the problems of the prior art, such as the limited blood glucose lowering effect of a single active ingredient and the tendency to develop drug resistance.

[0005] In order to achieve the above objectives, the present invention is realized by the following technical solutions.

[0006] A hesperetin-containing composition comprising hesperetin and compound X, said compound X being galangin or formononetin; Here, the mass ratio of hesperetin to galangin is 30:100, and the mass ratio of hesperetin to formononetin is 30:20.

[0007] Use of the composition in the preparation of a formulation for inhibiting α-glucosidase.

[0008] An α-glucosidase inhibitor, the active ingredients of which include hesperetin and galangin or hesperetin and formononetin, wherein the mass ratio of hesperetin to galangin is 30:100 and the mass ratio of hesperetin to formononetin is 30:20.

[0009] The application of said composition in the preparation of a hypoglycemic drug, wherein said hypoglycemic effect is achieved by inhibiting the activity of α-glucosidase and inhibiting carbohydrate digestion and absorption in order to control excessive postprandial blood glucose.

[0010] A blood sugar lowering drug, the active ingredients of which include hesperetin and galangin or hesperetin and formononetin, wherein the mass ratio of hesperetin to galangin is 30:100 and the mass ratio of hesperetin to formononetin is 30:20.

[0011] Within a limited range of mass concentration ratios, a synergistic technical effect of hesperetin and galangin, and hesperetin and formononetin is achieved.

[0012] The pharmaceutical agent according to the present invention contains pharma- ceutically acceptable carriers, solvents, diluents, excipients, and other medium mixtures, and can be prepared as powders, granules, capsules, injections, oral liquids, or tablets, as necessary.

[0013] The advantages of the technical solution of the present invention are as follows:

[0014] The compositions of hesperetin and galangin, and hesperetin and formononetin according to the present invention have a significant synergistic effect of inhibiting α-glucosidase, which is superior to the use of the flavonoid compounds alone, and can reduce the dosage of the drug used and suppress the occurrence of drug resistance. If formononetin or galangin is replaced with genistein, which has a similar chemical structure, the synergistic effect disappears.

[0015] In vitro inhibition tests of α-glucosidase using the Chou-Talalay method demonstrated that the compositions of hesperetin and galangin and hesperetin and formononetin of the present invention had significant synergistic effects on α-glucosidase at mass ratios of 30:100 and 30:20, respectively, and suppressed α-glucosidase activity by 50% (GI 50 ), 75% (G.I. 75 ) and 90% (G.I. 90 ) were found to have CI values ​​of less than 1.0 at inhibition rates, and the strength of the synergistic effect between the drugs was generally greater when the inhibition rate was higher than when it was lower. [Brief description of the drawings]

[0016] [Figure 1] 1 shows the inhibitory activity of the hesperetin compositions of Examples 1 and 4 against α-glucosidase. [Diagram 2] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and galangin (30:100). [Diagram 3] 1 is a Fa-CI trend graph showing the inhibition of α-glucosidase by a composition of hesperetin and galangin (30:100). [Figure 4] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and formononetin (30:20). [Diagram 5] 1 is a Fa-CI trend graph showing the inhibition of α-glucosidase by a composition of hesperetin and formononetin (30:20). [Figure 6] 1 shows the inhibitory activity of the hesperetin compositions of Examples 2 and 5 against α-glucosidase. [Figure 7] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and galangin (30:150). [Figure 8] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and formononetin (30:30). [Figure 9]1 shows the inhibitory activity of the hesperetin compositions of Examples 3 and 6 against α-glucosidase. [Figure 10] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and galangin (50:100). [Figure 11] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and formononetin (50:20). [Figure 12] 3 shows the inhibitory activity of the hesperetin composition of Comparative Example 1 against α-glucosidase. [Figure 13] 1 is a graph showing the inhibition of α-glucosidase by a composition of hesperetin and genistein (30:2). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Terms used in the present invention have the meanings commonly understood by those skilled in the art unless otherwise specified.

[0018] Hesperetin has the molecular formula C 16 H 14 O6, molecular weight is 302.28, CAS registration number is 520-33-2, structural formula is JPEG0007588274000001.jpg2648Galangin has the molecular formula C 15 H 10 O5, molecular weight is 270.24, CAS registration number is 548-83-4, structural formula is JPEG0007588274000002.jpg2540Formononetin has the molecular formula C 16 H 12 O4, molecular weight is 268.26, CAS registration number is 485-72-3, structural formula is JPEG0007588274000003.jpg2148α-glucosidase (from Saccharomyces cerevisiae, Sigma), 4-Nitrophenyl-α-D-galactopyranoside (pNPG, TOKYO Chemica Industry Co., LTD), Acarbose (TOKYO Chemica Industry Co., LTD), Hesperetin, Galangin, Formononetin (Solarbio Beijing), Millipore Simplicity water purification system (Millipore, France), Sodium phosphate buffer (pH 6.8, 0.1 mol L -1 ), Microplate reader TECAN infinite M200 PRO (Teacan Group Ltd., Switzerland).

[0019] The present invention will be described in more detail below with reference to data in conjunction with specific examples. The following examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention in any way.

[0020] Example 1 The composition of hesperetin and galangin has a mass ratio of hesperetin to galangin of 30:100, specifically, the concentrations of hesperetin and galangin in the composition are 30 μg / mL and 100 μg / mL, respectively.

[0021] Example 2 The composition of hesperetin and galangin has a mass ratio of hesperetin to galangin of 30:150, specifically, the concentrations of hesperetin and galangin in the composition are 30 μg / mL and 150 μg / mL, respectively.

[0022] Example 3 The composition of hesperetin and galangin has a mass ratio of hesperetin to galangin of 50:100, specifically, the concentrations of hesperetin and galangin in the composition are 50 μg / mL and 100 μg / mL, respectively.

[0023] Example 4 A composition of hesperetin and formononetin, wherein the mass ratio of hesperetin to formononetin is 30:20, specifically, the concentrations of hesperetin and formononetin in the composition are 30 μg / mL and 20 μg / mL, respectively.

[0024] Example 5 A composition of hesperetin and formononetin, wherein the mass ratio of hesperetin to formononetin is 30:30, specifically, the concentrations of hesperetin and formononetin in the composition are 30 μg / mL and 30 μg / mL, respectively.

[0025] Example 6 A composition of hesperetin and formononetin, in which the mass ratio of hesperetin to formononetin is 50:20, specifically, the concentrations of hesperetin and formononetin in the composition are 50 μg / mL and 20 μg / mL, respectively.

[0026] Testing the hypoglycemic effect of hesperetin compositions Testing Method: 0.25 U / mL α-glucosidase solution and 5 mmol / mL substrate 4-nitrophenyl-α-D-galactopyranoside (pNPG) solution were added in a volume of 0.1 mol L -1 The solution was prepared in PBS buffer at pH 6.8.

[0027] 100 μL of sample solution was added to each well, followed by 40 μL of α-glucosidase (0.25 U / mL) and reacting at 37°C for 15 minutes. Then, 60 μL of 5 mmol / mL substrate 4-nitrophenyl-α-D-galactopyranoside (pNPG) was added and reacted at 37°C for 15 minutes, after which the signal was measured at a wavelength of 405 nm using a microplate reader.

[0028] The test sample solutions were the hesperetin compositions described in Examples 1 to 6. First, hesperetin, galangin, and formononetin were each prepared into a mother solution of 10 mg / mL using dimethyl sulfoxide (DMSO), and then sample solutions of specific concentrations of hesperetin, galangin, formononetin, and the composition were prepared using PBS buffer.

[0029] The positive control was acarbose (350 μg / mL), the blank group contained neither sample nor enzyme, and the sample blank group contained no enzyme.

[0030] Calculation formula: Inhibition rate = [1-(OD 試料 -OD 試料ブランク ) / (OD 陰性対照 -OD ブランク )] × 100% The CI value is calculated using software called CompuSyn to evaluate the synergistic effect between drugs.

[0031] The Combination Index (CI) was used to represent the strength of synergy between drugs, where CI<1 indicates synergy between drugs, and drug combination can enhance the efficacy of each individual drug; the smaller the CI value, the stronger the synergy; CI=1 indicates an additive effect between drugs, and drug combination linearly superimposes the efficacy of each individual drug; and CI>1 indicates an antagonistic effect between drugs, and drug combination reduces the efficacy of each drug.

[0032] 1. Inhibitory activity of the hesperetin compositions of Examples 1 and 4 against α-glucosidase The inhibitory activity against α-glucosidase by the hesperetin compositions of Examples 1 and 4 is shown in FIG. 1: the inhibition rates at the corresponding mass concentrations of hesperetin 30 μg / mL, galangin 100 μg / mL, formononetin 20 μg / mL, and acarbose 350 μg / mL were 45.2 ± 3.2%, 56.32 ± 4.5%, 60.07 ± 5.3%, and 46.25 ± 3.5%, respectively. The inhibition rate by the composition of hesperetin and galangin (30 + 100 μg / mL) was 92.8 ± 6.4%, and the inhibition rate by hesperetin and formononetin (30 + 20 μg / mL) was 77.31 ± 4.5%, indicating that the combined use of the compositions significantly increased the inhibitory activity against α-glucosidase.

[0033] The inhibitory activity against α-glucosidase was detected at different concentration gradients of a composition of hesperetin and galangin with a mass ratio of 30:100. The concentration gradients of the composition of hesperetin and galangin were (μg / mL): 30+100, 15+50, 7.5+25, 3.75+12.5, the concentration gradients of hesperetin were (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradients of galangin were (μg / mL): 100, 50, 25, 12.5. The results are shown in Figure 2. The inhibitory activity against α-glucosidase was increased at different concentration gradients of a composition of hesperetin and galangin with a mass ratio of 30:100. FIG. 3 shows a Fa-CI trend graph for a composition of hesperetin and galangin in a mass ratio of 30:100. As can be seen from FIG. 3, both hesperetin and galangin had CI values ​​of 1.0 or less, demonstrating a synergistic effect.

[0034] A composition of hesperetin and formononetin with a mass ratio of 30:20 was detected to have inhibitory activity against α-glucosidase with different concentration gradients, and the concentration gradients of the hesperetin and formononetin composition were (μg / mL): 30 + 20, 15 + 10, 7.5 + 5, 3.75 + 2.5, the concentration gradient of hesperetin was (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradient of formononetin was (μg / mL): 20, 10, 5, 2.5. The results are shown in Figure 4. The composition of hesperetin and formononetin with a mass ratio of 30:20 also increased the inhibitory activity against α-glucosidase with different concentration gradients. FIG. 5 shows a Fa-CI trend graph of a composition of hesperetin and formononetin in a mass ratio of 30:20. As can be seen from FIG. 5, both hesperetin and formononetin had CI values ​​of 1.0 or less, demonstrating a synergistic effect.

[0035] The combination indices (CI) for the hesperetin compositions of Examples 1 and 4 are shown in Table 1.

[0036] JPEG0007588274000004.jpg48147Data were obtained from three independent experiments and are expressed as mean ± standard deviation.

[0037] As can be seen from the results in Table 1, the combination index CI for the combined use of hesperetin and galangin (30:100) and hesperetin and formononetin (30:20) was both less than 1, indicating a synergistic effect. Among these, the combination index for the hesperetin and galangin composition was GI 75 and G.I. 90 Both were less than 0.60, indicating strong synergy, and the mean combination index (CI avg ) is 0.48, and the combination coefficient of the composition of hesperetin and formononetin is GI 75 and G.I. 90 Both were less than 0.6, indicating a strong synergistic effect, and the mean combination index (CI avg ) was 0.56.

[0038] 2. Inhibitory activity of the hesperetin compositions of Examples 2 and 5 against α-glucosidase The inhibitory activity against α-glucosidase by the hesperetin compositions of Examples 2 and 5 is shown in FIG. 6: the inhibition rates at the corresponding mass concentrations of hesperetin 30 μg / mL, galangin 150 μg / mL, formononetin 30 μg / mL, and acarbose 350 μg / mL were 45.2 ± 3.2%, 84.4 ± 7.5%, 65.2 ± 4.3%, and 46.25 ± 3.5%, respectively. The inhibition rate by the composition of hesperetin and galangin (30 + 150 μg / mL) was 85.7 ± 6.7%, and the inhibition rate by hesperetin and formononetin (30 + 30 μg / mL) was 71.6 ± 3.5%, indicating that the combined use of the compositions did not significantly increase the inhibitory activity against α-glucosidase.

[0039] The inhibitory activity against α-glucosidase of a composition of hesperetin and galangin with a mass ratio of 30:150 was detected at different concentration gradients. The concentration gradients of the composition of hesperetin and galangin were (μg / mL): 30+150, 15+75, 7.5+37.5, 3.75+18.75, the concentration gradient of hesperetin was (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradient of galangin was (μg / mL): 150, 75, 37.5, 18.75. The results are shown in Figure 7.

[0040] The inhibitory activity against α-glucosidase of a composition of hesperetin and formononetin in a mass ratio of 30:30 was detected at different concentration gradients. The concentration gradients of the composition of hesperetin and formononetin were (μg / mL): 30+30, 15+15, 7.5+7.5, 3.75+3.75, the concentration gradient of hesperetin was (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradient of formononetin was (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradient of formononetin was (μg / mL): 30, 15, 7.5, 3.75. The results are shown in Figure 8.

[0041] The combination indices (CI) for the hesperetin compositions of Examples 2 and 5 are shown in Table 2.

[0042] JPEG0007588274000005.jpg50147Data were obtained from three independent experiments and are expressed as mean ± standard deviation.

[0043] As can be seen from the results in Table 2, the combination coefficients CI for the combination of hesperetin and galangin (30:150) and hesperetin and formononetin (30:30) were both greater than 1, indicating antagonistic effects.

[0044] 3. Inhibitory activity of the hesperetin compositions of Examples 3 and 6 against α-glucosidase The inhibitory activity against α-glucosidase by the hesperetin compositions of Examples 3 and 6 is shown in FIG. 9: the inhibition rates at the corresponding mass concentrations of hesperetin 50 μg / mL, galangin 100 μg / mL, formononetin 20 μg / mL, and acarbose 350 μg / mL were 63.4 ± 4.2%, 56.32 ± 4.5%, 60.07 ± 5.3%, and 46.25 ± 3.5%, respectively. The inhibition rate by the composition of hesperetin and galangin (50 + 100 μg / mL) was 75.5 ± 5.3%, and the inhibition rate by hesperetin and formononetin (50 + 20 μg / mL) was 71.31 ± 3.5%, indicating that the combined use of the compositions did not significantly increase the inhibitory activity against α-glucosidase.

[0045] The inhibitory activity against α-glucosidase of a composition of hesperetin and galangin with a mass ratio of 50:100 was detected at different concentration gradients. The concentration gradients of the composition of hesperetin and galangin were (μg / mL): 50+100, 25+50, 12.5+25, 6.25+12.5, the concentration gradient of hesperetin was (μg / mL): 50, 25, 12.5, 6.25, and the concentration gradient of galangin was (μg / mL): 100, 50, 25, 12.5, and the results are shown in Figure 10.

[0046] The inhibitory activity against α-glucosidase of a composition of hesperetin and formononetin with a mass ratio of 50:20 was detected at different concentration gradients. The concentration gradients of the composition of hesperetin and formononetin were (μg / mL): 50+20, 25+10, 12.5+5, 6.25+2.5, the concentration gradient of hesperetin was (μg / mL): 50, 25, 12.5, 6.25, and the concentration gradient of formononetin was (μg / mL): 20, 10, 5, 2.5. The results are shown in Figure 11.

[0047] The combination indices (CI) for the hesperetin compositions of Examples 3 and 6 are shown in Table 3.

[0048] JPEG0007588274000006.jpg49147Data were obtained from three independent experiments and are expressed as mean ± standard deviation.

[0049] As can be seen from the results in Table 3, the combination coefficients CI for the combined use of hesperetin and galangin (50:100) and hesperetin and formononetin (50:20) were both greater than 1, indicating antagonistic effects.

[0050] Comparative Example 1 Genistein has a structure similar to that of formononetin and has the molecular formula C 15 H 10 O5, molecular weight is 270.24, CAS registration number is 446-72-0, structural formula is JPEG0007588274000007.jpg2148 A composition of hesperetin and genistein, in which the mass ratio of hesperetin to genistein is 30:2, specifically, the concentrations of hesperetin and genistein are 30 μg / mL and 2 μg / mL, respectively.

[0051] The inhibitory activity of the hesperetin and genistein composition of Comparative Example 1 against α-glucosidase is shown in Figure 12: the inhibitory rates of α-glucosidase by 30 μg / mL hesperetin, 2 μg / mL genistein, and 350 μg / mL acarbose were 45.2 ± 3.2%, 47.7 ± 3.3%, and 46.25 ± 3.5%, respectively, and the inhibitory rate by the hesperetin and genistein composition (30 + 2 μg / mL) was 53.3 ± 2.7%, indicating that the combined use of the compositions slightly increased the inhibitory activity against α-glucosidase.

[0052] The inhibitory activity against α-glucosidase of a composition of hesperetin and genistein in a mass ratio of 30:2 was detected at different concentration gradients. The concentration gradients of the hesperetin and genistein composition were (μg / mL): 30+2, 15+1, 7.5+0.5, 3.75+0.25, the concentration gradient of hesperetin was (μg / mL): 30, 15, 7.5, 3.75, and the concentration gradient of genistein was (μg / mL): 2, 1, 0.5, 0.25. The results are shown in Figure 13.

[0053] The combination index (CI) of the hesperetin composition of Comparative Example 1 is shown in Table 4.

[0054] JPEG0007588274000008.jpg29147Data were obtained from three independent experiments and are expressed as mean ± standard deviation.

[0055] As can be seen from the results in Table 4, when hesperetin and genistein (30:2) composition was used in combination, the inhibitory activity against α-glucosidase increased, while the combination coefficient CI when hesperetin and genistein (30:2) composition was used in combination was greater than 1, indicating an antagonistic effect.

[0056] Comparative Example 2 This example shows a situation where the combination of each monomeric compound with hesperetin has no synergistic effect, where each monomeric compound is selected from morin, luteolin, myricetin, herbacetin, dihydromorin, naringenin, fisetin, baicalein, apigenin, kaempferide, scaviolide, chrysin, genkwanin, vitexin, phloretin, biochanin A and calycosin.

[0057] First, according to the above method, the α-glucosidase inhibition rate of each monomer compound at the corresponding concentration was tested, and is shown in Table 5 below.

[0058] JPEG0007588274000009.jpg100147 Next, each monomer compound was combined with hesperetin, and the inhibition rate of α-glucosidase by the composition was measured, and is shown in Table 6 below.

[0059] JPEG0007588274000010.jpg254135JPEG0007588274000011.jpg164135As can be seen from Table 6, in the combination of each of the above monomer compounds with hesperetin, the composition has a lower inhibition rate than that of the single compound, and actually exhibits an antagonistic effect, without any synergistic effect.

[0060] Comparative Example 3 This example shows a situation where the combination of each monomeric compound with galangin has no synergistic effect, where each monomeric compound is selected from morin, vitexin, kaempferide, apigenin, kaempferol, dihydromorin, fisetin, naringenin, myricetin, luteolin, daidzein, biochanin A, phloretin, isoliquiritigenin, scaviolide and delphinidin.

[0061] First, according to the above method, the α-glucosidase inhibition rate of each monomer compound at the corresponding concentration was tested, and is shown in Table 7 below.

[0062] JPEG0007588274000012.jpg95147 Next, each monomer compound was combined with galangin, and the inhibition rate of α-glucosidase by the composition was measured, as shown in Table 8 below.

[0063] JPEG0007588274000013.jpg246135JPEG0007588274000014.jpg127135As can be seen from Table 8, in the combination of each of the above monomeric compounds with galangin, the composition has a lower inhibition rate than that of the single compound, and actually exhibits an antagonistic effect, but has no synergistic effect.

[0064] Comparative Example 4 This example shows that the combination of each monomeric compound with formononetin has no synergistic effect, where each monomeric compound is selected from morin, vitexin, apigenin, 3-O-methylquercetin, kaempferol, dihydromorin, fisetin, naringenin, myricetin, luteolin, kaempferide, baicalein, vinstoxycoside B, herbacetin, daidzein, calycosin, phloretin, isoliquiritigenin, scaviolide and delphinidin.

[0065] First, according to the above method, the α-glucosidase inhibition rate of each monomer compound at the corresponding concentration was tested, and is shown in Table 9 below.

[0066] Next, each monomer compound was combined with formononetin, and the inhibition rate of α-glucosidase by the composition was measured, as shown in Table 10 below.

[0067] JPEG0007588274000016.jpg242135JPEG0007588274000017.jpg219135As can be seen from Table 10, in the combination of each of the above monomeric compounds with formononetin, the composition has a lower inhibition rate than that of the single compound, and actually exhibits an antagonistic effect, but has no synergistic effect.

[0068] The above examples are only for illustrating the technical solutions of the present invention, and are not intended to limit them. Although the present invention has been described in detail with reference to the above examples, those skilled in the art may modify the technical solutions described in the above examples or equivalently replace some of the technical features thereof, and these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions claimed for protection by the present invention.

Claims

1. Hesperetin and compound X, wherein compound X is galangin or formononetin; Here, the hesperetin-containing composition for α-glucosidase inhibition is characterized in that the mass ratio of hesperetin to galangin is 30:100, and the mass ratio of hesperetin to formononetin is 30:

20.

2. A composition comprising hesperetin and compound X, wherein compound X is galangin or formononetin, The α-glucosidase inhibitory preparation is characterized in that the mass ratio of hesperetin to galangin is 30:100, and the mass ratio of hesperetin to formononetin is 30:

20.

3. An alpha-glucosidase inhibitor, characterized in that the active ingredients include hesperetin and galangin or hesperetin and formononetin, wherein the mass ratio of hesperetin to galangin is 30:100 and the mass ratio of hesperetin to formononetin is 30:

20.

4. A method for treating hesperetin and compound X, wherein compound X is galangin or formononetin, Here, the mass ratio of hesperetin to galangin is 30:100, and the mass ratio of hesperetin to formononetin is 30:20, which is a hypoglycemic drug.

5. The blood glucose lowering drug according to claim 4, wherein the blood glucose lowering effect is achieved by inhibiting the activity of α-glucosidase and inhibiting the digestion and absorption of carbohydrates for the purpose of controlling excessive postprandial blood glucose.

6. A hypoglycemic drug, the active ingredients of which include hesperetin and galangin or hesperetin and formononetin, wherein the mass ratio of hesperetin to galangin is 30:100 and the mass ratio of hesperetin to formononetin is 30:

20.

7. The drug of claim 6, characterized in that the drug comprises a pharmaceutically acceptable carrier, solvent, diluent, excipient or other vehicle.

8. The drug according to claim 6, characterized in that the dosage form of the drug is selected from powder, granules, capsules, injections, oral liquids or tablets.

Citation Information

Patent Citations

  • Use of flavonoids to increase the bioavailability of hesperetin

    JP2012522030A

  • antimicrobial composition

    JP2018501233A

  • Pharmaceutical composition for prevention or treatment of fatty liver

    JP2018534323A

  • Cytochrome P450 3A inhibitors and enhancers

    US20030166584A1

  • Method and composition for preventing and treating viral infections

    WO2019045677A1